'Egfr' presentation slideshows

Introduction to the Basics of Signal Transduction

890 views • 75 slides

Victor Cohen, MDCM, FRCPC Department of Oncology Segal Cancer Center

885 views • 62 slides

Novel and Emerging Therapeutic Strategies in the Management of Non-Small Cell Lung Cancer

Novel and Emerging Therapeutic Strategies in the Management of Non-Small Cell Lung Cancer. Matthew Gubens , MD, MS Associate Professor, Thoracic Medical Oncology University of California, San Francisco San Francisco, California. Grand Rounds Program Steering Committee.

956 views • 54 slides

Objectives

Biologic Targeting in RT Bill McBride Dept. Radiation Oncology David Geffen School Medicine UCLA, Los Angeles, Ca. wmcbride@mednet.ucla.edu. Objectives. Understand the relationship between molecular carcinogenesis and radiation response Know how to target receptor tyrosine kinases

610 views • 51 slides

1.38k views • 50 slides

1.25k views • 49 slides

715 views • 48 slides

Promising Future Biomarkers For Colorectal Cancer: Focus on Targeted Therapies

753 views • 42 slides

Marcello Tiseo U.O. Oncologia Medica Azienda Ospedaliero-Universitaria di Parma

EGFR e meccanismi di resistenza agli inibitori. Marcello Tiseo U.O. Oncologia Medica Azienda Ospedaliero-Universitaria di Parma. Mutazioni di EGFR e TKIs: punti fermi. Netto impatto dei trattamenti in OS: 2-3 anni 8 studi random di I linea vs CT

730 views • 40 slides

William Pao, MD, PhD Assistant Director, Personalized Cancer Medicine

Genotype-Driven Lung Cancer Treatment AAAS-FDLI Colloquium on Personalized Medicine October 27, 2009. William Pao, MD, PhD Assistant Director, Personalized Cancer Medicine Vanderbilt-Ingram Cancer Center Nashville, TN. Disclosure Information.

575 views • 39 slides

The Continuation of Biologic Agents Beyond Progression: Does It Make Sense?

The Continuation of Biologic Agents Beyond Progression: Does It Make Sense?. Axel Grothey Mayo Clinic College of Medicine Rochester, MN. Continuation of Chemotherapy Beyond Progression. FOLFOX ? FOLFIRI Tournigand FOLFIRI ? FOLFOX Tournigand LV5FU2 ? FOLFIRI FOCUS LV5FU2 ? FOLFOX FOCUS

484 views • 34 slides

Targeting Glioblastoma: EGFR and Novel Approaches to Therapy

Targeting Glioblastoma: EGFR and Novel Approaches to Therapy. Glioblastoma: The Current State of Affairs. No Improvement With Temozolomide Dose Intensification or Treatment Prolongation. Treatment at Recurrence. Glioblastoma: Improving Outcomes.

918 views • 32 slides

Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan

Expression of EGFR, ERRB2, and KIT in Adult Soft Tissue Sarcomas: A Clinicopathological Study of 281 Cases. Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan National Cancer Center, Tokyo Japan. Purpose.

392 views • 24 slides

Aiming at the Wrong Target? Discussion of Abstracts CRA3507 (Alberts) and 3508 (Goldberg)

Aiming at the Wrong Target? Discussion of Abstracts CRA3507 (Alberts) and 3508 (Goldberg). Louis M. Weiner, MD Lombardi Comprehensive Cancer Center Georgetown University Medical Center. Potential Conflicts Relevant to this Presentation. Consultant, Stock Options Merrimack Pharmaceuticals

379 views • 22 slides

BR.21 Study Design

245 views • 14 slides

Lorenza Landi Istituto Toscano Tumori, Ospedale Civile, Livorno

Clinical Implications of Micro-RNA in Cancer. Lorenza Landi Istituto Toscano Tumori, Ospedale Civile, Livorno. Background. Anti-EGFR Mabs cetuximab and panitumumab - alone or combination with chemotherapy - demonstrated efficacy in KRAS wild type mCRC patients.

475 views • 14 slides

Supervivencia global en pacientes con CNMP con afectación hepática según EGFR

Supervivencia global en pacientes con CNMP con afectación hepática según EGFR. EGFR mutado (n = 8) SG= not reached. EGFR wild type (n = 43) SG=13 mo. Total n = 51. p = 0.023 * HR: 0.208 (95% CI 0.047 - 0.921).

147 views • 3 slides

Progression-Free Survival Times

Ligand expression of the EGFR ligands amphiregulin, epiregulin, and amplification of the EGFR gene to predict for treatment efficacy in KRAS wild-type mCRC patients treated with cetuximab plus CAPIRI and CAPOX: Analysis of the randomized AIO CRC-0104 trial. 1.0. 1.0. 1.0. EGFR-FISH:

130 views • 1 slides

A B C

161 views • 1 slides

ERK Signaling

Ag. Integrins. TGR-CD3 Complex. CaCn. EGFR. N. SHC. C. GRB2. GRB2. PYK2. ZAP70. AC. RTK. SOS. SHC. EPAC. VHR. GTP. GTP. G b. G a. G g. SOS. SOS. PLC b. PLC g. LAT. Rap1. PKA. PAK. Src. FAK. MKP. FAK. KSR. Raf1. PKC. MP1. c-Raf. Rac. PI3K. PP1/ PP2. MNK1/2.

135 views • 1 slides